

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | 2 | — | — | — | 2 |
| Esophagitis | D004941 | HP_0100633 | K20 | — | 2 | — | — | — | 2 |
| Drug common name | Linaprazan |
| INN | linaprazan |
| Description | Linaprazan is an experimental drug for the treatment of gastroesophageal reflux disease (GERD). Unlike the proton-pump inhibitors (PPIs) which are typically used to treat GERD, linaprazan is a potassium-competitive acid blocker (P-CAB). Linaprazan was developed by AstraZeneca, but it was not successful in clinical trials.
|
| Classification | Small molecule |
| Drug class | proton pump inhibitors, not dependent on acid activation |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12 |
| PDB | — |
| CAS-ID | 248919-64-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL497011 |
| ChEBI ID | — |
| PubChem CID | 9951066 |
| DrugBank | — |
| UNII ID | E0OU4SC8DP (ChemIDplus, GSRS) |
